Grant Holder |
Researcher |
Completed project Institute Amount Awarded Duration Type of Award |
Define the mechanistic basis of BRCA1 induced mitotic arrest in response to paclitaxel
Dr Paul Harkin and Dr Jennifer Quinn aim to determine how the BRCA1 gene works in combination with other molecules in the cell which to affect the way the breast cancer drug Taxol functions.
Dr Paul Harkin and Dr Jennifer Quinn aim to determine how the BRCA1 gene works in combination with other molecules in the cell which to affect the way the breast cancer drug Taxol functions.
Dr Paul Harkin and Dr Jennifer Quinn at Queens University in Belfast have found that the breast cancer causing defective BRCA1 gene plays an important role in determining the effectiveness of the drug Taxol in killing breast cancer cells. Essentially, if BRCA1 is normal then Taxol is effective at killing tumour cells, however, when BRCA1 is defective (in breast cancer) then this drug does not work. Scientists are certain that this is due to BRCA1 working in combination with other molecules thus affecting the way the drug functions. Paul and Jennifer will continue their studies to discover how BRCA1 does this. This research will allow clinicians in the future to see which breast cancer patients will respond to this treatment.
| Title | The role of of BRCA1 in the cellular response to chemotherapy |
| Year | 2004 |
| Authors | Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. |
| Title | BRCA1 is a differential modulator of chemotherapy induced apoptosis. |
| Year | 2003 |
| Authors | Quinn JE and Harkin DP |
| Title | BRCA1 is a differential modulator of chemotherapy induced apoptosis |
| Year | 2004 |
| Authors | Dr Jennifer Quinn |
| Title | BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents |
| Year | 2004 |
| Authors | Quinn JE and Harkin DP |
| Title | BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents |
| Year | 2004 |
| Authors | Quinn JE and Harkin DP |